Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

EPT Disclosure

9 Jun 2006 12:36

Deutsche Bank AG London09 June 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Deutsche Bank AG LondonCompany dealt in Cambridge Antibody Technology Group PlcClass of relevant security to which the Ordinarydealings being disclosed relate (Note 1) Date of dealing 08/06/2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 1,804 ÂŁ13.107 ÂŁ13.086 Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 9,362 ÂŁ13.125 ÂŁ13.085 (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3) e.g. CFDCFD Long 1,300 ÂŁ13.107CFD Long 400 ÂŁ13.09CFD Short 104 ÂŁ13.086CFD Short 104 ÂŁ13.086 (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities Exercise Type, e.g. Expiry Option money purchasing, to which the option American,e.g. call option varying etc. relates (Note 5) price European etc. Date paid/received per unit (Note 3) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingto the voting rights of any relevant securities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form isreferenced. If none, this should be stated. NONE Date of disclosure 09/06/2006 Contact name Kelly-Jade Ledwich Telephone number 020 7545 7804 Name of offeree/offeror with which connected AstraZeneca PlcNature of connection (Note 6) Adviser to the offeror Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Aug 20197:00 amRNSNet Asset Value(s)
16th Aug 201911:05 amRNSSecond Price Monitoring Extn
16th Aug 201911:00 amRNSPrice Monitoring Extension
15th Aug 20193:17 pmRNSHalf-year Report
13th Aug 20197:00 amRNSCirc re. Reverse Tender Offer & Class Meetings
26th Jul 20197:00 amRNSAnnouncement re Markel CATCo Investment Management
26th Jul 20197:00 amRNSReturn of cap-reverse tender offer & share buyback
22nd Jul 20197:00 amRNSNet Asset Value(s)
26th Jun 20192:37 pmRNSNet Asset Value(s)
5th Jun 201910:54 amRNSHolding(s) in Company
3rd Jun 20197:00 amRNSPortfolio Update
28th May 20194:00 pmRNSDirector/PDMR Shareholding
23rd May 20194:31 pmRNSResult of Annual General Meeting
20th May 20197:00 amRNSNet Asset Value(s)
13th May 20196:09 pmRNSHolding(s) in Company
29th Apr 20197:00 amRNSNet Asset Value(s)
23rd Apr 20197:00 amRNSFinal Results
15th Apr 20197:00 amRNSUpdate re government enquiry at Markel CATCo
4th Apr 20197:00 amRNSNet Asset Value(s)
26th Mar 201912:15 pmRNSResult of Meeting
14th Mar 20197:00 amRNSNet Asset Value(s)
11th Mar 20193:30 pmRNSPartial waiver of management fee re side pockets
28th Feb 20195:48 pmRNSCirc re. restructuring of Company & Class Meetings
26th Feb 20191:53 pmRNSDirectorate Change
19th Feb 201912:00 pmRNSPortfolio Update
7th Feb 20197:00 amRNSNet Asset Value(s) and Portfolio Update
21st Jan 20197:00 amRNSUpdate on Investment Manager
10th Jan 20192:03 pmRNSDirector/PDMR Shareholding
10th Jan 20192:02 pmRNSDirector/PDMR Shareholding
4th Jan 201912:15 pmRNSHolding(s) in Company
3rd Jan 201911:44 amRNSDirector/PDMR Shareholding
21st Dec 20187:00 amRNSNet Asset Value(s)
18th Dec 20183:30 pmRNSPortfolio Update
18th Dec 20183:30 pmRNSDiscount control measures
17th Dec 20184:30 pmRNSHolding(s) in Company
10th Dec 20187:00 amRNSHolding(s) in Company
7th Dec 20184:35 pmRNSPrice Monitoring Extension
7th Dec 20187:00 amRNSPortfolio Update
7th Dec 20187:00 amRNSAnnouncement regarding Markel CATCo
22nd Nov 20182:05 pmRNSSecond Price Monitoring Extn
22nd Nov 20182:00 pmRNSPrice Monitoring Extension
22nd Nov 20187:00 amRNSNet Asset Value(s) & Portfolio Update
18th Oct 20187:00 amRNSNet Asset Value and Portfolio Update
1st Oct 20187:00 amRNSDirector/PDMR Shareholding
27th Sep 20184:05 pmRNSHolding(s) in Company
24th Sep 20181:25 pmRNSDirector/PDMR Shareholding
24th Sep 20181:23 pmRNSDirector/PDMR Shareholding
21st Sep 201811:05 amRNSTransaction in Own Shares
20th Sep 20187:00 amRNSNet Asset Value(s)
29th Aug 20183:55 pmRNSShare interests acquisition by CEO of Inv Manager

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.